GR1006835B - Synthetic method for 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole and the sesquihydrate of the sodium salt thereof in crystalline form and the application of apharmaceutical formulation thereof. - Google Patents
Synthetic method for 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole and the sesquihydrate of the sodium salt thereof in crystalline form and the application of apharmaceutical formulation thereof.Info
- Publication number
- GR1006835B GR1006835B GR20090100396A GR20090100396A GR1006835B GR 1006835 B GR1006835 B GR 1006835B GR 20090100396 A GR20090100396 A GR 20090100396A GR 20090100396 A GR20090100396 A GR 20090100396A GR 1006835 B GR1006835 B GR 1006835B
- Authority
- GR
- Greece
- Prior art keywords
- pantoprazole
- sesquihydrate
- sodium salt
- sodium
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the gastric acid secretion inhibitor, pantoprazole, in solid state and in particular in the crystalline form of the sodium salt of pantoprazole, and the application of a medicinal formulation thereof.The present invention provides a procedure comprising mixing of a thioether, about 1.0 equivalent of an active chloro-containing oxidizing agent, preferably calcium hypochlorite, and about 4.5 equivalents of an alkali metal base, to obtain the sulfoxide – pantoprazole. The procedure further comprises the contact of the sulfoxide with a sodium ion source, preferably sodium hydroxide, to provide the sodium salt of the sulfoxide.The invention also provides the use of pantoprazole sodium sesquihydrate for the preparation of a medicinal formulation, in the form of tablets coated with an enteric film, which reduces the gastric acid secretion.Thus, the invention provides a new procedure for the preparation of crystalline forms of pantoprazole sodium sesquihydrate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20090100396A GR1006835B (en) | 2009-07-15 | 2009-07-15 | Synthetic method for 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole and the sesquihydrate of the sodium salt thereof in crystalline form and the application of apharmaceutical formulation thereof. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20090100396A GR1006835B (en) | 2009-07-15 | 2009-07-15 | Synthetic method for 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole and the sesquihydrate of the sodium salt thereof in crystalline form and the application of apharmaceutical formulation thereof. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1006835B true GR1006835B (en) | 2010-07-05 |
Family
ID=41716640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20090100396A GR1006835B (en) | 2009-07-15 | 2009-07-15 | Synthetic method for 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole and the sesquihydrate of the sodium salt thereof in crystalline form and the application of apharmaceutical formulation thereof. |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1006835B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004111029A2 (en) * | 2003-06-10 | 2004-12-23 | Teva Pharmaceutical Industries Ltd. | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
| WO2008045777A2 (en) * | 2006-10-06 | 2008-04-17 | Dr. Reddy's Labortories, Ltd. | A process for the preparation of benzimidazole derivatives and their salts |
-
2009
- 2009-07-15 GR GR20090100396A patent/GR1006835B/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004111029A2 (en) * | 2003-06-10 | 2004-12-23 | Teva Pharmaceutical Industries Ltd. | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
| WO2008045777A2 (en) * | 2006-10-06 | 2008-04-17 | Dr. Reddy's Labortories, Ltd. | A process for the preparation of benzimidazole derivatives and their salts |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI367759B (en) | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid | |
| MX2010010647A (en) | Process for preparing orally administered dabigatran formulations. | |
| NO20092464L (en) | Solid forms of racemic ilaprazole | |
| NO20085332L (en) | Delayed release duloxetine hydrogen chloride formulations | |
| DK1246622T3 (en) | New substituted benzimidazole dosage forms and methods for their use | |
| MY125399A (en) | Benzimidazole compound crystal. | |
| MX2011008389A (en) | Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of copd. | |
| PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
| NO20052474L (en) | Amortized form of esomeprazole salts | |
| YU53801A (en) | Potassium salt of (s) - omeprazole | |
| EA201071053A1 (en) | CRYSTAL DERIVATIVE OF BENZIMIDAZOLE | |
| NZ588909A (en) | Iminopyridine derivatives and use thereof | |
| MX2009010167A (en) | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent. | |
| WO2004111029A8 (en) | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole | |
| JP2016508516A5 (en) | ||
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| TW200726764A (en) | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | |
| WO2010095144A3 (en) | Process for preparation of proton pump inhibitors | |
| IN2014DN03416A (en) | ||
| PH12019500919A1 (en) | Esomeprazole~containing complex capsule and preparation method therefor | |
| GR1006835B (en) | Synthetic method for 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole and the sesquihydrate of the sodium salt thereof in crystalline form and the application of apharmaceutical formulation thereof. | |
| CA2648538A1 (en) | Oral rapid release pharmaceutical formulation for pyridylmethylsulfinyl-benzimidazoles | |
| WO2008001392A3 (en) | An improved process for the preparation of pantoprazole and its pharmaceutically acceptable salts | |
| WO2010018175A3 (en) | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer | |
| WO2010137040A3 (en) | Novel pharmaceutical compositions of ranolazine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PG | Patent granted |